|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 February 2002, Vol. 99, No. 4, pp. 1314-1319
NEOPLASIA
The chimeric anti-CD20 antibody rituximab induces apoptosis in
B-cell chronic lymphocytic leukemia cells through a p38 mitogen
activated protein-kinase-dependent mechanism
Irene Munk Pedersen,
Anne
Mette Buhl,
Pia Klausen,
Christian H. Geisler, and
Jesper Jurlander
From the Leukemia Laboratory, Department of Hematology,
The Finsen Centre, Rigshospitalet, Copenhagen, Denmark.
Antibodies against CD20 can activate complement and induce
antibody-dependent cellular cytotoxicity (ADCC) in B lymphocytes. In
B-cell lines, such antibodies also induce apoptosis. In this study, the
expression and function of CD20 on B-cell chronic lymphocytic leukemia
(B-CLL) cells were analyzed. Flow cytometric analysis demonstrated that B-CLL cells express CD20 with a fluorescence intensity that is significantly weaker than that of normal
CD5+ and CD5 B cells and that of
malignant CD5 low-grade non-Hodgkin lymphoma cells. A
small population of cells from healthy donors that have an
expression pattern of CD5 and CD20 identical to that of B-CLL cells
were identified, and this population was confirmed to be of T lineage,
not B lineage. Culture of freshly isolated B-CLL cells in the
presence of the chimeric anti-CD20 antibody rituximab and a
cross-linking F(ab)2 fragment, resulted in dose- and
time-dependent induction of apoptosis. The induction of apoptosis
occurred under conditions in which the influence of complement
activation and ADCC was negligible. Cross-linking of rituximab induced
strong and sustained phosphorylation of the 3 mitogen activated protein
(MAP) kinases c-Jun NH2-terminal protein kinase,
extracellular signal-regulated kinase, and p38.
Introduction of the p38 inhibitor SB203580 into the system completely
blocked signaling downstream of p38, as evidenced by the absence of
MAPKAP K2 activity, and significantly reduced the degree of
anti-CD20-induced apoptosis. These results demonstrate that
cross-linking of rituximab bound to CD20 on freshly isolated B-CLL
cells induces apoptosis through a signaling pathway that is dependent
on p38 MAP-kinase activation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Mishima, N. Sugimura, Y. Matsumoto-Mishima, Y. Terui, K. Takeuchi, S. Asai, D. Ennishi, H. Asai, M. Yokoyama, K. Kojima, et al.
An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Clin. Cancer Res.,
May 15, 2009;
15(10):
3624 - 3632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lapalombella, B. Yu, G. Triantafillou, Q. Liu, J. P. Butchar, G. Lozanski, A. Ramanunni, L. L. Smith, W. Blum, L. Andritsos, et al.
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Blood,
December 15, 2008;
112(13):
5180 - 5189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Racila, B. K. Link, W.-K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, et al.
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Clin. Cancer Res.,
October 15, 2008;
14(20):
6697 - 6703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stolz, G. Hess, P. S. Hahnel, F. Grabellus, S. Hoffarth, K. W. Schmid, and M. Schuler
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
Blood,
October 15, 2008;
112(8):
3312 - 3321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhou, W. Hu, and X. Qin
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Oncologist,
September 1, 2008;
13(9):
954 - 966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV
Blood,
August 15, 2008;
112(4):
1205 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Clin. Cancer Res.,
March 1, 2008;
14(5):
1561 - 1570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz
Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia
J. Leukoc. Biol.,
June 1, 2006;
79(6):
1157 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney
Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas
Mol. Cancer Ther.,
December 1, 2005;
4(12):
2037 - 2044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Smith, F. Jin, and I. Joshi
Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts
Mol. Cancer Ther.,
December 1, 2004;
3(12):
1693 - 1699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Jazirehi, M. I. Vega, D. Chatterjee, L. Goodglick, and B. Bonavida
Inhibition of the Raf-MEK1/2-ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab
Cancer Res.,
October 1, 2004;
64(19):
7117 - 7126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Eisenbeis, A. Grainger, B. Fischer, R. A. Baiocchi, L. Carrodeguas, S. Roychowdhury, L. Chen, A. L. Banks, T. Davis, D. Young, et al.
Combination Immunotherapy of B-Cell Non-Hodgkin's Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study
Clin. Cancer Res.,
September 15, 2004;
10(18):
6101 - 6110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bezombes, S. Grazide, C. Garret, C. Fabre, A. Quillet-Mary, S. Muller, J.-P. Jaffrezou, and G. Laurent
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains
Blood,
August 15, 2004;
104(4):
1166 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Olszewski and M. L. Grossbard
Empowering Targeted Therapy: Lessons from Rituximab
Sci. Signal.,
July 13, 2004;
2004(241):
pe30 - pe30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. X. Xing, X. F. Hu, G. A. Pietersz, H. L. Hosick, and I. F. C. McKenzie
Cripto: A Novel Target for Antibody-Based Cancer Immunotherapy
Cancer Res.,
June 1, 2004;
64(11):
4018 - 4023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stein, Z. Qu, S. Chen, A. Rosario, V. Shi, M. Hayes, I. D. Horak, H. J. Hansen, and D. M. Goldenberg
Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
April 15, 2004;
10(8):
2868 - 2878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Eisenbeis, M. A. Caligiuri, and J. C. Byrd
Rituximab: Converging Mechanisms of Action in Non-Hodgkin's Lymphoma?
Clin. Cancer Res.,
December 1, 2003;
9(16):
5810 - 5812.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
J. Immunol.,
August 1, 2003;
171(3):
1581 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood,
June 15, 2003;
101(12):
4667 - 4679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sansonno, V. De Re, G. Lauletta, F. A. Tucci, M. Boiocchi, and F. Dammacco
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20
Blood,
May 15, 2003;
101(10):
3818 - 3826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Campas, J. M. Lopez, A. F. Santidrian, M. Barragan, B. Bellosillo, D. Colomer, and J. Gil
Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes
Blood,
May 1, 2003;
101(9):
3674 - 3680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bannerji, S. Kitada, I. W. Flinn, M. Pearson, D. Young, J. C. Reed, and J. C. Byrd
Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance
J. Clin. Oncol.,
April 15, 2003;
21(8):
1466 - 1471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, L. Smith, M. L. Hackbarth, I. W. Flinn, D. Young, J. H. Proffitt, and N. A. Heerema
Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab
Cancer Res.,
January 1, 2003;
63(1):
36 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Bertho, V. M. Blancheteau, N. Setterblad, B. Laupeze, J. M. Lord, B. Drenou, L. Amiot, D. J. Charron, R. Fauchet, and N. Mooney
MHC class II-mediated apoptosis of mature dendritic cells proceeds by activation of the protein kinase C-{delta} isoenzyme
Int. Immunol.,
August 1, 2002;
14(8):
935 - 942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
